Gilead Sciences (FRA:GIS) Piotroski F-Score: 9 (As of Jun. 27, 2026) — 50% Above Median


FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €108.26
GF Value €81.25
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Piotroski F-Score?

Gilead Sciences FRA:GIS -0.79% 75 Piotroski F-Score is 9 as of Jun. 27, 2026, which is 50% above its 10-year median of 6.00. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €81.25 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 981 Drug Manufacturers companies, Gilead Sciences ranks better than 99.9% on this metric.

Good Sign:

Piotroski F-Score is 9, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gilead Sciences has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Gilead Sciences's Piotroski F-Score or its related term are showing as below:

FRA:GIS' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 9

During the past 13 years, the highest Piotroski F-Score of Gilead Sciences was 9. The lowest was 4. And the median was 6.

Gilead Sciences  (FRA:GIS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gilead Sciences Piotroski F-Score Related Terms


Gilead Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Piotroski F-Score Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 7.00 6.00 8.00

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 8.00 8.00 9.00

FRA:GIS vs AMGN, PFE, BMY: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Piotroski F-Score falls into.


FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 1699.32 + 2600.304 + 1864.282 + 1748.165 = €7,912 Mil.
Cash Flow from Operations was 717.009 + 3500.016 + 2841.258 + 2200.56 = €9,259 Mil.
Revenue was 6139.227 + 6619.188 + 6767.096 + 6020.4 = €25,546 Mil.
Gross Profit was 4837.86 + 5282.4 + 5380.2 + 4770.475 = €20,271 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(52201.45 + 48310.107 + 49870.116 + 50405.642 + 48680.47) / 5 = €49893.557 Mil.
Total Assets at the begining of this year (Mar25) was €52,201 Mil.
Long-Term Debt & Capital Lease Obligation was €18,045 Mil.
Total Current Assets was €16,124 Mil.
Total Current Liabilities was €8,196 Mil.
Net Income was 1499.406 + 1128.953 + 1702.765 + 1216.375 = €5,547 Mil.

Revenue was 6459.337 + 6798.045 + 7228.395 + 6166.975 = €26,653 Mil.
Gross Profit was 5024.961 + 5379.871 + 5718.54 + 4742.475 = €20,866 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(51788.64 + 49774.891 + 49127.025 + 56340.225 + 52201.45) / 5 = €51846.4462 Mil.
Total Assets at the begining of last year (Mar24) was €51,789 Mil.
Long-Term Debt & Capital Lease Obligation was €20,485 Mil.
Total Current Assets was €15,633 Mil.
Total Current Liabilities was €11,417 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gilead Sciences's current Net Income (TTM) was 7,912. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gilead Sciences's current Cash Flow from Operations (TTM) was 9,259. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=7912.071/52201.45
=0.15156803

ROA (Last Year)=Net Income/Total Assets (Mar24)
=5547.499/51788.64
=0.10711807

Gilead Sciences's return on assets of this year was 0.15156803. Gilead Sciences's return on assets of last year was 0.10711807. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gilead Sciences's current Net Income (TTM) was 7,912. Gilead Sciences's current Cash Flow from Operations (TTM) was 9,259. ==> 9,259 > 7,912 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=18044.765/49893.557
=0.36166523

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=20485.05/51846.4462
=0.39511001

Gilead Sciences's gearing of this year was 0.36166523. Gilead Sciences's gearing of last year was 0.39511001. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=16124.465/8195.875
=1.96738786

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=15633.425/11417.275
=1.36927813

Gilead Sciences's current ratio of this year was 1.96738786. Gilead Sciences's current ratio of last year was 1.36927813. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gilead Sciences's number of shares in issue this year was 1254. Gilead Sciences's number of shares in issue last year was 1259. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=20270.935/25545.911
=0.79350997

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=20865.847/26652.752
=0.78287777

Gilead Sciences's gross margin of this year was 0.79350997. Gilead Sciences's gross margin of last year was 0.78287777. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=25545.911/52201.45
=0.48937167

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=26652.752/51788.64
=0.51464476

Gilead Sciences's asset turnover of this year was 0.48937167. Gilead Sciences's asset turnover of last year was 0.51464476. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+0
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gilead Sciences has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 9 mean?
Gilead Sciences (FRA:GIS) has a Piotroski F-Score of 9 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Gilead Sciences and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, Gilead Sciences' Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, Gilead Sciences ranks #1 out of 981 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Gilead Sciences' Piotroski F-Score too high?
Gilead Sciences' current Piotroski F-Score of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Gilead Sciences' value of 9 is 80% above this industry median. Based on the distribution chart, Gilead Sciences ranks #1 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Piotroski F-Score compare to AMGN and PFE?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #1 out of 981 companies for Piotroski F-Score. This places Gilead Sciences in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Gilead Sciences' value of 9 is 80% above this benchmark. Historically, Gilead Sciences' own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Piotroski F-Score is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €81.25, compared to a current price of €108.26 — trading 33.2% above its estimated fair value. The current Piotroski F-Score is 9, which is 50% above median its 10-year median of 6.00 and 80% above the Drug Manufacturers industry median of 5.00. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Piotroski F-Score is 9 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €108.26 is trading 33.2% above its estimated GF Value™ of €81.25. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Piotroski F-Score: 9 (50% above median its 10-year median of 6.00)
  • GF Value™: €81.25 vs. price of €108.26 (33.2% above fair value)
  • GF Score™: 75/100 with 3 warning signs
  • Industry Position: 80% above the Drug Manufacturers median (#1 of 981)

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€108.26
Price
€81.25
GF Value